Radiosensitization in head and neck cancer: do we have an alternative to platins? Role of taxanes

In the past few decades, concurrent chemoradiation has conclusively been established as the standard of care in resectable, locally advanced head and neck cancer. Platins until now have been the established radiosensitizer in all concurrent settings, including postoperative high-risk scenarios. However, retrospective and evolving data suggest that they have their limitations in terms of compatibility, toxicity, and intrinsic resistance. There is therefore the need to explore the scope of other agents that may address these issues through a different mode of action, a better toxicity profile, or preferably a combination of both. In recent years, taxanes have emerged as an effective chemotherapeutic agent for head and neck cancer for recurrent or metastatic disease and chemoinduction for downstaging before definitive treatment. In this article, the authors review the potential of taxanes as an alternative to platins in the concurrent setting.